LEQVIO® was well tolerated
over 18 months
Most common adverse reactions in
≥3% of patients treated
with
LEQVIO and more frequently than
placebo1

ªIncludes related terms such as injection site pain, erythema, and rash.
2.5% of patients discontinued LEQVIO vs 1.9% with placebo1
The safety profile of LEQVIO was consistent across all subgroups, including elderly, hepatic, and renally impaired patient populations1*
*LEQVIO was not studied in patients with end-stage
renal disease or severe hepatic impairment.
Injection site reactions were the most
common causes for treatment
discontinuation (0.2% of patients taking
LEQVIO vs 0% taking placebo).1
-
All were localized, predominantly mild,
or occasionally moderate4
THERE'S MORE TO KNOW ABOUT LEQVIO
Effective and sustained
LDL-C reduction is
possible for your patients1†

†Greater LDL-C reducation was maintained
during each 6-month dosing interval vs
placebo as a complement to a maximally
tolerated statin.